Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.5.2453

Targeting HSP90 Gene Expression with 17-DMAG Nanoparticles in Breast Cancer Cells  

Mellatyar, Hassan (Department of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences)
Talaei, Sona (Department of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences)
Nejati-Koshki, Kazem (Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences)
Akbarzadeh, Abolfazl (Stem Cell Research Center, Tabriz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.5, 2016 , pp. 2453-2457 More about this Journal
Abstract
Background: Dysregulation of HSP90 gene expression is known to take place in breast cancer. Here we used D,L-lactic-co-glycolic acid-polyethylene glycol-17-dimethylaminoethylamino-17-demethoxy geldanamycin (PLGA-PEG-17DMAG) complexes and free 17-DMAG to inhibit the expression of HSP90 gene in the T47D breast cancer cell line. The purpose was to determine whether nanoencapsulating 17DMAG improves the anti-cancer effects as compared to free 17DMAG. Materials and Methods: The T47D breast cancer cell line was grown in RPMI 1640 supplemented with 10% FBS. Encapsulation of 17DMAG was conducted through a double emulsion method and properties of copolymers were characterized by Fourier transform infrared spectroscopy and H nuclear magnetic resonance spectroscopy. Assessment of drug cytotoxicity was by MTT assay. After treatment of T47D cells with a given amount of drug, RNA was extracted and cDNA was synthesized. In order to assess HSP90 gene expression, real-time PCR was performed. Results: Taking into account drug load, IC50 was significant decreased in nanocapsulated 17DMAG in comparison with free 17DMAG. This finding was associated with decrease of HSP90 gene expression. Conclusions: PLGA-PEG-17DMAG complexes can be more effective than free 17DMAG in down-regulating of HSP90 expression, at the saesm time exerting more potent cytotoxic effects. Therefore, PLGA-PEG could be a superior carrier for this type of hydrophobic agent.
Keywords
Breast cancer; HSP90; 17DMAG-PLGA-PEG; T47D cell line;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Toikkanen S, Pylkkanen L, Joensuu H, et al (1997). Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer, 79, 1234-40.
2 Virnig BA, Tuttle TM, Shamliyan T, et al (2010). Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst, 102, 170-8.   DOI
3 Whitesell L, Lindquist SL (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer, 5, 761-772.   DOI
4 Wu GQ, Liu NN, Xue XL, et al (2014). Multiplex Real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy. Asian Pac J Cancer Prev, 15, 4153-8.   DOI
5 Zhang X, Hanamura N, Yamasita M, et al (2011). A case of lobular carcinoma in Situ presenting as a solid mass. Br J Radiol, 84, 48-50.
6 Arpino G, Bardou VJ (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.Breast Cancer Res, 6, 149-56.   DOI
7 Bojesen S, Pooley KA (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet, 45, 371-84.   DOI
8 Davaran S, Alimirzalu S, Nejati-Koshki K, et al (2014). Synthesis and study of physicochemical characteristics of Fe3O4 magnetic nanocomposites based on poly (Nisopropylacrylamide) for anti-cancer drugs delivery. Asian Pac J Cancer Prev, 15, 49-54.   DOI
9 Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, et al (2014). Molecular target therapy of AKT and NF-kB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 Cells. Asian Pac J Cancer Prev, 15, 4353-8.   DOI
10 Dilnawaz F, Singh A, et al (2010). Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials, 31, 3694-706.   DOI
11 Goldhirsch A, Wood WC (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22, 1736-47.   DOI
12 Dobo C, Stavale JN, Lima Fde O, et al (2013). HSP27 is Commonly Expressed in Cervical Intraepithelial Lesions of Brazilian Women. Asian Asian Pac J Cancer Prev, 14, 5007-10.   DOI
13 Early Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet, 378, 1707-16.   DOI
14 Ghasemali S, Nejati-Koshki K, Tafsiri E, et al (2013). Study of Inhibitory Effect of ${\beta}$-Cyclodextrin-HelenalinComplex on HTERT Gene Expression in T47D Breast Cancer Cell Line by Real Time Quantitative PCR (q-PCR). Asian Pac J Cancer Prev, 14, 6949-53.   DOI
15 Lindgren M, Rosenthal-Aizman K, et al (2006). Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell penetrating peptide. Biochem Pharmacol, 71, 416-25.   DOI
16 Guo W, Siegel D, Ross D, et al (2008). Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal catalyzed oxidation. J Pharm Sci, 97, 5147-57   DOI
17 Hosseininasab S, Pashaei-Asl R, Khandaghi AA, et al (2014). Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. Chem Biol Drug Des, 84, 307-15.   DOI
18 Karkoulis PK, Stravopodis DJ (2010). 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer, 10, 481.   DOI
19 Mestril R, Batey J (2014). Heat shock proteins protect skeletal muscle against frostbite injury. FASEB J, 28, 1102-43.
20 Makhnevych T, Houry WA (2012). The role of Hsp90 in protein complex assembly. Biochim Biophys Acta, 1823, 674-82.   DOI
21 Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al (2014). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-9.
22 Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, et al (2012). Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnol, 64, 719-26.   DOI
23 Rohl A, Rohrberg J, et al (2013). The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci, 38, 253-62.   DOI
24 Nejati-Koshki K, Mesgari M, Ebrahimi E, Abbasalizadeh F, et al (2014). Synthesis and in vitro study of cisplatin-loaded Fe3O4 nanoparticles modified with PLGA-PEG6000 copolymers in treatment of lung cancer. J Microencapsul, 31, 815-23.   DOI
25 Pourhassan-Moghaddam M, Rahmati-Yamchi M, Akbarzadeh A, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Research Letters, 8, 485.   DOI
26 Qu Zh, Dong H, et al (2013). Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway. Diagn Pathol, 8, 70.
27 Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al (2014). PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev, 15, 517-35.   DOI
28 Sharp S, Workman P (2006). Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res, 95, 323-348.
29 Tanaka T, Decuzzi P, Cristofanilli M, et al (2009). Nanotechnology for breast cancer therapy. Biomed Microdevices, 11, 49-63.   DOI
30 Sun X, Bristol JA, et al (2013). Hsp90 Inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol, 87, 10126-38.   DOI